bit.bio is a synthetic biology company providing human cells for research, drug discovery and cell therapy. The company applies a patented safe harbour gene-targeting approach (opti-ox™; Pawlowski 2017) to inducibly express transcription factor combinations that reprogram human induced pluripotent stem cells (iPSCs) into highly defined and mature human cell types.
The company has expertise in the underpinning science of synthetic biology and stem cells and also in manufacturing, and clinical translation.
